Victrex Retained Earnings (Accumulated Deficit) 2019-2024 | VTXPF
Victrex retained earnings (accumulated deficit) from 2019 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Victrex Annual Retained Earnings (Accumulated Deficit) (Millions of US $) |
2024 |
$505 |
2023 |
$531 |
2022 |
$547 |
2021 |
$609 |
2020 |
$535 |
2019 |
$519 |
2018 |
$593 |
2016 |
$ |
2015 |
$ |
2014 |
$ |
Victrex Quarterly Retained Earnings (Accumulated Deficit) (Millions of US $) |
2024-09-30 |
$505 |
2023-09-30 |
$531 |
2023-03-31 |
$510 |
2022-09-30 |
$547 |
2022-03-31 |
$540 |
2021-09-30 |
$609 |
2021-03-31 |
$576 |
2020-09-30 |
$535 |
2020-03-31 |
$525 |
2019-09-30 |
$519 |
2019-03-31 |
$481 |
2018-09-30 |
$593 |
Sector |
Industry |
Market Cap |
Revenue |
Basic Materials |
Chemicals - Plastics |
$1.092B |
$0.369B |
Victrex Plc engages in the manufacture and marketing of polymers. The company offers products under the Victrex, Aptiv, Vicote and Victrex Pipes brands. It operates through the Victrex Polymer Solutions and Invibio Biomaterial Solutions segments. Victrex Polymer Solutions segment focuses on the automotive, aerospace, electronics and energy markets. Invibio Biomaterial Solutions provides solutions for medical device manufacturers. Victrex Plc is headquartered in Thornton Cleveleys, United Kingdom.
|